The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
The Influence of Finasteride on the Development of Prostate Cancer
Open accessAbstract
BACKGROUND: Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. METHODS: In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study. RESULTS: Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo. CONCLUSIONS: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationCANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS
HULL, G. W., RABBANI, F., ABBAS, F., WHEELER, T. M., KATTAN, M. W., & SCARDINO, P. T. (2002) · Journal of Urology · doi:10.1016/s0022-5347(01)69079-7 · Cited by 964
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., & Kantoff, P. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3320 · Cited by 873
Albertsen, P. C. (1998) · JAMA · doi:10.1001/jama.280.11.975 · Cited by 717
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
Ross, R. K., Bernstein, L., Pike, M. C., Henderson, B. E., Lobo, R. A., Stanczyk, F. Z., & Shimizu, H. (1992) · The Lancet · doi:10.1016/0140-6736(92)90927-u · Cited by 495
Hormones and prostate cancer: Current perspectives and future directions
Hsing, A. W., Reichardt, J. K. V., & Stanczyk, F. Z. (2002) · The Prostate · doi:10.1002/pros.10108 · Cited by 208
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationLippman, S. M., Klein, E. A., Goodman, P. J., Lucia, M. S., Thompson, I. M., Ford, L. G., Parnes, H. L., Minasian, L. M., Gaziano, J. M., Hartline, J. A., et al. (2009) · JAMA · doi:10.1001/jama.2008.864 · Cited by 2,122
Self-citationMcConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Self-citationKlein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1437 · Cited by 1,787
Self-citationCancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Polyamines and cancer: old molecules, new understanding
Gerner, E. W., & Meyskens, F. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1454 · Cited by 1,159
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,113
Self-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citationPotential Pitfalls of Disease-Specific Guidelines for Patients with Multiple Conditions
Tinetti, M. E., Bogardus, S. T., & Agostini, J. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmsb042458 · Cited by 927
Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G., Peracchia, G., & Corti, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1145 · Cited by 815
Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., & de Koning, H. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp001 · Cited by 796
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Mechanisms linking physical activity with cancer
McTiernan, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2325 · Cited by 744
Changes in circulating microRNA levels associated with prostate cancer
Bryant, R. J., Pawlowski, T., Catto, J. W. F., Marsden, G., Vessella, R. L., Rhees, B., Kuslich, C., Visakorpi, T., & Hamdy, F. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.595 · Cited by 715
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Adiposity and cancer risk: new mechanistic insights from epidemiology
Renehan, A. G., Zwahlen, M., & Egger, M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3967 · Cited by 654
Epidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Giovannucci, E., & Michaud, D. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.050 · Cited by 543
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Self-citationGiovannucci, E., Liu, Y., Platz, E. A., Stampfer, M. J., & Willett, W. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22788 · Cited by 522
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Prevention and early detection of prostate cancer
Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70211-6 · Cited by 495
Self-citationThe androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3419 · Cited by 470
Morgentaler, A., & Traish, A. M. (2009) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 462
Hormonal Therapy for Prostate Cancer
Desai, K., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 447
Molecular targets of phytochemicals for cancer prevention
Lee, K. W., Bode, A. M., & Dong, Z. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3017 · Cited by 426
Quantifying the role of PSA screening in the US prostate cancer mortality decline
Etzioni, R., Tsodikov, A., Mariotto, A., Szabo, A., Falcon, S., Wegelin, J., diTommaso, D., Karnofski, K., Gulati, R., Penson, D. F., et al. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9083-8 · Cited by 423
Damber, J.-E., & Aus, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60729-1 · Cited by 418
Grönberg, H., Adolfsson, J., Aly, M., Nordström, T., Wiklund, P., Brandberg, Y., Thompson, J., Wiklund, F., Lindberg, J., Clements, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00361-7 · Cited by 407
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Cancer chemoprevention: a rapidly evolving field
Steward, W. P., & Brown, K. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.280 · Cited by 367
Reflections on the Discovery and Significance of Estrogen Receptor β
Koehler, K. F., Helguero, L. A., Haldosén, L.-A., Warner, M., & Gustafsson, J.-A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0027 · Cited by 360
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L., Thompson, I. M., Kristal, A. R., Santella, R. M., Probstfield, J. L., Moinpour, C. M., Albanes, D., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji009 · Cited by 356
Self-citationRodriguez, C., Freedland, S. J., Deka, A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Thun, M. J., & Calle, E. E. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0754 · Cited by 354
Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
Gong, Z., Neuhouser, M. L., Goodman, P. J., Albanes, D., Chi, C., Hsing, A. W., Lippman, S. M., Platz, E. A., Pollak, M. N., Thompson, I. M., et al. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0477 · Cited by 352
Self-citationThe 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases
Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012) · Advances in Urology · doi:10.1155/2012/530121 · Cited by 333
Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., & Kuntz, K. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021659 · Cited by 326
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer
Thompson, I. M., Chi, C., Ankerst, D. P., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj307 · Cited by 323
Self-citationAndrogen deprivation therapy for prostate cancer: Current status and future prospects
Miyamoto, H., Messing, E. M., & Chang, C. (2004) · The Prostate · doi:10.1002/pros.20115 · Cited by 317
Medical treatments for male and female pattern hair loss
Rogers, N. E., & Avram, M. R. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.07.001 · Cited by 309
Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates
Leitzmann, M., & Rohrmann, S. (2012) · Clinical Epidemiology · doi:10.2147/clep.s16747 · Cited by 304
THE RELATIVE IMPACT AND FUTURE BURDEN OF PROSTATE CANCER IN THE UNITED STATES
CHAN, J. M., JOU, R. M., & CARROLL, P. R. (2004) · Journal of Urology · doi:10.1097/01.ju.0000142068.66876.53 · Cited by 303
Finasteride 5 mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon?
Mondaini, N., Gontero, P., Giubilei, G., Lombardi, G., Cai, T., Gavazzi, A., & Bartoletti, R. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00563.x · Cited by 299
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
ANDRIOLE, G., BOSTWICK, D., BRAWLEY, O., GOMELLA, L., MARBERGER, M., TINDALL, D., BREED, S., SOMERVILLE, M., RITTMASTER, R., & REDUCE STUDY GROUP (2004) · Journal of Urology · doi:10.1097/01.ju.0000139320.78673.2a · Cited by 291
Active Surveillance for Prostate Cancer: Progress and Promise
Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9738 · Cited by 290
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Thompson, I. M., Goodman, P. J., Tangen, C. M., Parnes, H. L., Minasian, L. M., Godley, P. A., Lucia, M. S., & Ford, L. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215932 · Cited by 288
Self-citationBuvat, J., Maggi, M., Guay, A., & Torres, L. O. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02783.x · Cited by 283
Evaluation and treatment of male and female pattern hair loss
Olsen, E. A., Messenger, A. G., Shapiro, J., Bergfeld, W. F., Hordinsky, M. K., Roberts, J. L., Stough, D., Washenik, K., & Whiting, D. A. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.04.008 · Cited by 280
ANDRIOLE, G., BRUCHOVSKY, N., CHUNG, L. W. K., MATSUMOTO, A. M., RITTMASTER, R., ROEHRBORN, C., RUSSELL, D., & TINDALL, D. (2004) · Journal of Urology · doi:10.1097/01.ju.0000139539.94828.29 · Cited by 277
Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02157.x · Cited by 275
Androgenetic Alopecia: An Update of Treatment Options
Kelly, Y., Blanco, A., & Tosti, A. (2016) · Drugs · doi:10.1007/s40265-016-0629-5 · Cited by 274
Active surveillance for early‐stage prostate cancer: Review of the current literature
Dall'Era, M. A., Cooperberg, M. R., Chan, J. M., Davies, B. J., Albertsen, P. C., Klotz, L. H., Warlick, C. A., Holmberg, L., Bailey, D. E., Wallace, M. E., et al. (2008) · Cancer · doi:10.1002/cncr.23373 · Cited by 273
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Self-citationCKD and the Risk of Incident Cancer
Lowrance, W. T., Ordoñez, J., Udaltsova, N., Russo, P., & Go, A. S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060604 · Cited by 269
Jahn, J. L., Giovannucci, E. L., & Stampfer, M. J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29408 · Cited by 268
Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial
Lucia, M. S., Epstein, J. I., Goodman, P. J., Darke, A. K., Reuter, V. E., Civantos, F., Tangen, C. M., Parnes, H. L., Lippman, S. M., La Rosa, F. G., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm117 · Cited by 266
Self-citationNovel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer
Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., & Nakagawa, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00656.x · Cited by 263
O’Keefe, E. B., Meltzer, J. P., & Bethea, T. N. (2015) · Frontiers in Public Health · doi:10.3389/fpubh.2015.00051 · Cited by 259
Ankerst, D. P., Hoefler, J., Bock, S., Goodman, P. J., Vickers, A., Hernandez, J., Sokoll, L. J., Sanda, M. G., Wei, J. T., Leach, R. J., et al. (2014) · Urology · doi:10.1016/j.urology.2014.02.035 · Cited by 236
Self-citationTestosterone for the aging male; current evidence and recommended practice
Jones, H. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s190 · Cited by 204
Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408925102 · Cited by 192
Platz, E. A., & Giovannucci, E. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.002 · Cited by 180
French administrative health care database (SNDS): The value of its enrichment
Scailteux, L.-M., Droitcourt, C., Balusson, F., Nowak, E., Kerbrat, S., Dupuy, A., Drezen, E., Happe, A., & Oger, E. (2019) · Therapies · doi:10.1016/j.therap.2018.09.072 · Cited by 138
Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort
Brasky, T. M., Lampe, J. W., Potter, J. D., Patterson, R. E., & White, E. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0318 · Cited by 109
Andropause: is androgen replacement therapy indicated for the aging male?
Hijazi, R. A., & Cunningham, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104518 · Cited by 105
Borst, S. E., Yarrow, J. F., Conover, C. F., Nseyo, U., Meuleman, J. R., Lipinska, J. A., Braith, R. W., Beck, D. T., Martin, J. S., Morrow, M., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00592.2013 · Cited by 98
The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer
Capper, C. P., Rae, J. M., & Auchus, R. J. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0259-0 · Cited by 89
The importance of long-term follow up of participants in clinical trials
Cuzick, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02038-4 · Cited by 101
5α-Reductases in human physiology: an unfolding story
Traish, A. M. (2012) · Endocrine Practice · doi:10.4158/ep12108.ra · Cited by 57
Effects of oral finasteride on erectile function in a rat model
Zhang, M.-G., Wu, W., Zhang, C.-M., Wang, X.-J., Gao, P.-J., Lu, Y.-L., & Shen, Z.-J. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02661.x · Cited by 35
Gustafsson, J.-A. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0479 · Cited by 19
Matsumoto, A. M., & Bremner, W. J. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00019-5 · Cited by 18
Song, Y., Tangen, C., Goodman, P., Parnes, H. L., Lucia, M. S., Thompson, I. M., & Kristal, A. R. (2008) · The Prostate · doi:10.1002/pros.20637 · Cited by 8
Self-citation
Metadata
- Authors
- Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., Carlin, S. M., Ryan, A., Szczepanek, C. M., Crowley, J. J., & Coltman, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-17
- Volume
- 349
- Issue
- 3
- Pages
- 215-224
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133929387
- Cited by
- 2,518
- References
- 17
- FWCI
- 128.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.